Sign-up for SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX investment picks
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Repros Therapeutics Inc.
(“Repros Therapeutics” or the “Company”) (NASDAQ: RPRX) concerning
possible violations of federal securities laws.
The Rosen Law Firm announces that it is investigating potential
securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
By Erin McCarthy
Repros Therapeutics Inc. said it was notified by the U.S. Food and Drug Administration that there isn't enough clinical information to hold a planned pre-investigational new drug application meeting in November.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.